MedTrace Logo

Feasibility of Circulating Tumour DNA (ctDNA) Analysis Using Automated Capillary Blood Sampling

NCT07310537 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 35

Last updated 2026-01-06

No results posted yet for this study

Summary

The goal of this observational study is to investigate whether circulating tumor-derived DNA (ctDNA) can be reliably detected and analyzed in blood obtained through automated capillary sampling in adult patients (≥21 years) with colorectal liver metastases (CRLM).

The main question it aims to answer is:

* Can ctDNA be detected in small volumes of capillary blood collected using an automated sampling device?
* Do ctDNA levels measured in capillary blood agree with those measured in venous blood from the same patients?

Researchers will compare ctDNA measurements from capillary blood to those from venous blood (reference standard) to see if capillary sampling provides reliable results for ctDNA analysis.

Participants will:

* Provide a small blood sample through automated capillary collection.
* Provide a venous blood sample during the same study visit for comparison.

Conditions

  • Colorectal Cancer (Diagnosis)
  • Colorectal Liver Metastasis (CRLM)
  • Circulating Tumor DNA (ctDNA)

Interventions

OTHER

Blood Collection - TAP® Device

K2EDTA BD Microtainer

OTHER

Blood Collection - Venous

10 mL EDTA Collection Tube

Sponsors & Collaborators

Principal Investigators

  • Cornelis Verhoef, MD, PhD · Erasmus Medical Center

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2025-11-17
Primary Completion
2026-11-30
Completion
2027-11-30

Countries

  • Netherlands

Study Locations

More Related Trials

Entities

Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07310537 on ClinicalTrials.gov